Chemkart Invests ₹2 Crore In Wholly Owned Subsidiary Via Rights Issue; Shares Rise 3.03%

Mumbai, March 12: Chemkart India Limited informed the exchange on Thursday that it has made an additional investment of ₹2.00 crore in its wholly owned subsidiary Easy Raw Materials Private Limited through a rights issue, with the company’s shares closing 3.03% higher at ₹106.00 on the BSE.

Chemkart Invests ₹2 Crore In Subsidiary Through Rights Issue

Chemkart India Limited disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 that it subscribed to 20,00,000 equity shares of Easy Raw Materials Private Limited.

The shares were issued at a face value of ₹10 each and allotted at par, resulting in a total investment of ₹2.00 crore. The investment forms part of the utilisation of proceeds raised through the company’s Initial Public Offer prospectus dated July 10, 2025.

According to the regulatory filing, the funds will be used towards commissioning the manufacturing unit of the subsidiary.

Easy Raw Materials Private Limited remains a wholly owned subsidiary of the company, with Chemkart holding 100% shareholding both before and after the allotment.

Share Price Movement On March 12, 2026

Chemkart India Limited share price settled higher in Thursday’s trading session on the BSE following the disclosure.

The stock closed at ₹106.00 on March 12, 2026, rising ₹3.12 or 3.03% compared with the previous close of ₹102.88, according to exchange data.

During the session, the stock traded between an intraday high of ₹107.90 and a low of ₹98.90. The company’s market capitalisation stood at approximately ₹128.25 crore at the close of trading.

Subsidiary Structure And Financial Details

Easy Raw Materials Private Limited is engaged in the manufacturing of nutraceuticals and health supplements and was incorporated in 2020 in India.

As per details disclosed in the exchange filing, the subsidiary has an authorised share capital of ₹10.00 crore divided into 1,00,00,000 equity shares of ₹10 each.

Post allotment of the new shares, the paid up share capital increased to ₹6.51 crore comprising 65,10,000 equity shares.

Financial disclosures in the filing indicated that as of March 31, 2025 the subsidiary reported nil turnover, a loss after tax of ₹12.68 lakh and a negative net worth of ₹11.93 lakh.

The transaction falls within the ambit of related party transactions as the entity is a wholly owned subsidiary, though the company stated it was conducted on an arm’s length basis.

Conclusion

The additional capital infusion is intended to support operational development of the subsidiary’s manufacturing infrastructure, aligning with the objectives outlined in Chemkart’s IPO documents.

No governmental or regulatory approvals were required for the transaction, and the consideration for the investment was entirely in cash, according to the exchange disclosure.

Source:

• https://www.bseindia.com/stock-share-price/chemkart-india-ltd/chemkart/544442/
• https://www.bseindia.com/xml-data/corpfiling/AttachLive/2f0dad49-363a-4d73-b55a-cffc5a6d804f.pdf